Lumida
/INBX
⌘K
Inhibrx Biosciences Inc

Inhibrx Biosciences Inc

INBX
$87.39USD-1.89%-1.68 today

MARKET CAP

1.3B

P/E (TTM)

FWD P/E

DAY RANGE

$85 – $92

52W RANGE

$21
$155

AI Summary

Stalk
Sell NowMedium

INBX is entrenched in a Stage 4 decline, marked by sequential lower highs and lower lows beneath its down-sloping EMAs and the 50SMA. Relief rallies consistently stall and reverse at dynamic resistance, while oversold oscillators lack exhaustion. The medium-term bias remains bearish, so optimal execution is to sell into rallies toward the EMA/50SMA resistance zone via rejection.

  • FDA accepted Ozekibart's BLA, PDUFA target set for April 2027.
  • Ozekibart could address first systemic therapy gap in chondrosarcoma.
  • Negative P/E of –11.09 and latest EPS –$2.15 highlight deep losses.
Full analysis →
Insider Trades5 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Sep 12, 2024BuyINBXMark LappeChief Executive Officer40,000$15.73$1.3B-43.72%+325.26%$629.1K+2.95%Sell Now
Sep 6, 2024BuyINBXMark LappeChief Executive Officer44,000$15.25$1.3B-43.72%+325.26%$671.1K+2.28%Sell Now
Aug 29, 2024BuyINBXMark LappeChief Executive Officer40,000$14.92$1.3B-43.72%+325.26%$596.8K+7.08%Sell Now
Aug 20, 2024BuyINBXMark LappeChief Executive Officer40,000$12.96$1.3B-43.72%+325.26%$518.3K+70.44%Sell Now
May 28, 2024SellINBXBrendan P. EckelmanChief Scientific Officer300,000$34.30$1.3B-43.72%+325.26%$10.3M-14.74%Sell Now